Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 84.13% | 104.92% | -38.48% | 13.94% | -5.63% |
| Total Depreciation and Amortization | 70.08% | 59.88% | -0.19% | 0.19% | -1.39% |
| Total Amortization of Deferred Charges | -17.07% | -28.44% | -24.86% | 6.92% | -42.01% |
| Total Other Non-Cash Items | -419.65% | -461.94% | 49.29% | 1,752.98% | 75.49% |
| Change in Net Operating Assets | -129.66% | -144.83% | -30.37% | 484.75% | 94.57% |
| Cash from Operations | -32.82% | 26.84% | -68.75% | 58.71% | 24.09% |
| Capital Expenditure | -38.71% | -1,060.26% | -14.77% | 41.65% | 61.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -38.71% | -1,060.26% | -191.48% | 41.65% | 61.09% |
| Total Debt Issued | 3.74% | -4.36% | 43.07% | -46.93% | 1.41% |
| Total Debt Repaid | 17.63% | 100.00% | 40.27% | 26.10% | -- |
| Issuance of Common Stock | -43.46% | -52.30% | -31.90% | 138.06% | 292.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -21.51% | -14.77% | -0.53% | -27.37% | -2.91% |
| Foreign Exchange rate Adjustments | 234.43% | -84.21% | 198.07% | -22,952.94% | -277.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -307.62% | -98.95% | 320.69% | 281.39% | 71.59% |